



Follow us on Twitter:

@dirkpilat

@drtomround

@celfes

# Essential Knowledge Updates

[www.elearning.rcgp.org.uk](http://www.elearning.rcgp.org.uk)

RCGP Annual Conference 2016

Dr Dirk Pilat Medical Director for eLearning

Dr Chris Elfes ECU Steering Group Chair and EKC Clinical Lead

Dr Thomas Round ECU Development Fellow



Royal College of  
General Practitioners

# Today's fantastic session!


- eLearning
  - ECU overview
  - EKC Taster
  - Suspected Cancer + Briefings
  - Type 2 diabetes + Briefings
  - Chronic heart failure
  - Bronchiolitis
  - EKC answers
- Dirk Pilat  
Thomas Round  
Chris Elfes  
Thomas Round  
Chris Elfes  
Dirk Pilat  
Thomas Round  
Chris Elfes

*Any questions?.....or have a rest!*

# Continuous professional development for primary care physicians – Why?

- Patients expect rightly expect highest degree of professionalism
- Doctors need to balance traditional values and latest scientific expertise
- Need to respond to educational needs that arise during patient contact and continuously being up to date on the ever shifting evidence base around diagnostic and therapeutic methods
- Particularly difficult for general practitioners (GPs)
- Newly qualified doctors' knowledge not enough to last a life time

# Estimated time for doubling of medical knowledge in years



# CPD in the good old days



- Seminars
- Problem based small group learning
- Journals
- Textbooks
- Conferences
- Journal Clubs

# CPD via elearning: a success story

- National transition to computer-based practice management systems has effectively placed a PC on every GP's desk
- On-line CPD facilitates quick response to perceived educational need arising during a consultation without having to wait for a seminar, book or conference to come around
- Immediacy of internet based learning one of the secrets to its success over the last 15 years and its broad uptake
- No need to plan
- Immediacy of learning

# eLearning doesn't have to be alone in front of your PC

- Use practice, journal group and faculty meetings to present, share and discuss new learning
- Extend your personal educational network and use Twitter, Facebook Groups and mailing-lists
- Use your smart devices for spontaneous learning (both formal and informal)



# What's on offer?

Three different elearning programs for different needs:

- Essential Learning Updates + Challenges
- 2 minutes to change your practice
- 62 in depth courses covering all curriculum statements

All accessible to RCGP members for free

**Essential Knowledge Updates & Challenges**

Welcome to the Essential Knowledge Update Programme

Six monthly focused **Essential Knowledge Updates** on new and changing knowledge central to everyday practice.

**Essential Knowledge Challenge**, an online applied knowledge test that help users to assess their existing knowledge and highlight their learning needs.

Meet the **Essential Knowledge Update and Challenge Team**

**WINNER**  
e-learning awards 2014

In October 2014 the Essential Knowledge Update and Challenge Programme won the **Gold Award for Best eLearning Project** (third sector) at the eLearning Awards. Please click the image to the left to find out more.

Updates & Challenges by Clinical Content | Updates & Challenges by Non Clinical Content | EKU Podcasts and Screencast | EKU Hot Topics

RCGP Learning  
Essential CPD for primary care

Home > Site pages > Clinical Content

Go to RCGP website Help About Us

Search

- Promoting health and preventing disease
- Genetics in Primary Care
- Acutely ill People
- Children and Young People
- Older Adults
- Women's Health
- Men's Health
- Sexual Health
- End of Life Care
- Two Minutes to Change Your Practice
- Mental Health Problems
- Intellectual Difficulties
- Cardiovascular Health
- Digestive Health
- Misuse of Drugs and Alcohol
- Metabolic Problems
- Neurological Problems
- Respiratory Health
- Musculoskeletal Problems
- Skin Problems

RCGP Learning  
Health Education: Does salt matter?

RCGP Learning  
Single Inhaler Therapy for Asthma

RCGP Learning  
You have diagnosed non-alcoholic fatty liver disease (NAFLD)- What next?

RCGP Learning  
Change in Practice - HIV testing

The government has set targets to reduce salt intake to just 3g/day by 2025, from the current average of 8g. This screencast will highlight the evidence driving this target, and help you guide your patients towards the cardiovascular benefits which can be achieved through this reduction.

Traditionally, inhaled therapy for asthma is a combination of "preventer" and "reliever" medications. There is, however, an alternative: single inhaler therapy. This module will explain what this is and how to use it.

Increasingly, patients are being diagnosed with non-alcoholic fatty liver disease. This module aims to change your practice on monitoring and management for these patients based on their risk of disease progression. It outlines the need to calculate a "fibrosis score" and offers specific guidance on lifestyle changes these patients can be supported to make in order to avoid complications.

HIV has a much better prognosis when it is diagnosed early. Testing can be done in primary care with no need for extensive pre-test counselling. This module aims to change practice by increasing the number of HIV tests requested in primary care and also gives a brief update on issues relating to patients who have already been diagnosed.



# Essential Knowledge Updates (EKU)

## Introduction

Dr Thomas Round, GP and ECU Development Fellow  
@drtomround

# Essential Knowledge Updates (EKU) Programme

- Since its inception in May 2008, the EKU Programme has now been accessed by over 45,000 users
  - 488 major and minor modules
  - 26 podcasts
  - 12 screencasts
  - 21 hot topics (2015)
  - 3 editions of EKU Journal Watch (2016)
  - 850 Challenge questions.
- The content of the programme covers 96% of the RCGP curriculum
- 66% of the audited content (EKU2-14) is still usable

# EKU Programme

## Essential Knowledge Updates & Challenges

Welcome to the Essential Knowledge Update Programme



Six monthly focused **Essential Knowledge Updates** on new and changing knowledge central to everyday practice.

**Essential Knowledge Challenge**, an online applied knowledge test that help users to assess their existing knowledge and highlight their learning needs.

[Meet the Essential Knowledge Update and Challenge Team](#)

WINNER

e-learning  
awards 2014

In October 2014 the Essential Knowledge Update and Challenge Programme won the **Gold Award for Best eLearning Project** (third sector) at the eLearning Awards. Please click the image to the left to find out more.

Updates & Challenges by Clinical Content

Updates & Challenges by Non Clinical Content

EKU Podcasts

EKU Screencasts

EKU Hot Topics

EKU Journal Watch

# EKU Programme

## Major Topics

These Updates are based on major items of new and changing knowledge.

You may find it helpful to identify your learning needs before reading the Update by completing the Self Assessment first. Alternatively, you may prefer to complete the Self Assessment afterwards to confirm your learning

 Combined Pharmacotherapy & Behavioural Interventions for Smoking Cessation 

 Self Assessment: Combined Pharmacotherapy & Behavioural Interventions for Smoking Cessation

 Wheeze & Asthma in Young Children 

 Self Assessment: Wheeze & Asthma in Young Children

 Menopause: Diagnosis & Management 

 Self Assessment: Menopause - Diagnosis & Management

 Care of Dying Adults in the Last Days of Life 

 Self Assessment: Care of Dying Adults in the Last Days of Life

 Management of Chronic Heart Failure 

 Self Assessment: Management of Chronic Heart Failure

 Alcohol Use Disorders 

 Self Assessment: Alcohol Use Disorders

## Briefings

Short briefings based on items of new & changing knowledge.

 [Access the Minor Briefings Here](#)

## RCGP Research Paper of the Year Briefings

 [Access the RPY Briefings here](#)

## Essential Knowledge Challenge 18

Two separate 25 item Essential Knowledge Challenges. The questions in both Challenges are sourced from the major updates and briefings found within the current Essential Knowledge Update 18. Each Challenge contains a different set of 25 questions, balanced across the available modules.

- Essential Knowledge Challenge 18 (1): With Instant Answers
- Essential Knowledge Challenge 18 (2): With Certificate (answers available April 2017)

Please note that Challenge 18 will be launched in January 2017 and the answers to Essential Knowledge Challenge 18(2) questions will be published in April 2017.

## Learning Tools

These tools have been designed to aid you in assessing your practice & applying your new knowledge. The forms for audit, significant event audit, multi-source feedback (MSF), patient satisfaction questionnaire (PSQ) and Patient Complaints / Cause for Concern / Positive Feedback can aid you in meeting your revalidation requirements.

 [Access the Learning Tools Here](#)

# EKU Programme

## Essential Knowledge Update 2017.1: January 2017

Your progress 

The RCGP Essential Knowledge Updates (EKU) are a fantastic elearning CPD resource, written for GPs by GPs, updating you on new and changing evidence to inform your practice. This is the seventeenth EKU release which we hope continues to offer interesting and diverse evidence based elearning content.

EKU 2017.1 consists of 5 major modules which were selected following a comprehensive search and assessment of new guidelines and evidence, and were felt to have the most relevance and potential to impact on the day to day practice of busy GPs.

Topics within this release are managing common infections, non-alcoholic fatty liver disease, sepsis, supporting people with dementia and their carers and treatment of Alzheimer's disease and opioid use disorder.

We hope you find all of the diverse topics included within this Update interesting and relevant to your practice, and continue to use EKU as an essential part of your CPD.



 Acknowledgements



**RCGP Learning**

Essential CPD for primary care

# Essential Knowledge Challenge (EKC)

Dr Chris Elfes, FRCGP



Royal College of  
General Practitioners

# Question 1: Investigation of cough

A 68-year-old ex-smoker has had a dry cough for eight weeks. Examination is normal. He has COPD and hypertension. His regular medications are: aspirin 75 mg daily, atorvastatin 80 mg daily, amlodipine 5 mg daily and tiotropium inhaler once daily.

**Which of the following is the SINGLE MOST appropriate INITIAL investigation? Select ONE option only.**

- A. Chest x-ray
- B. ECG
- C. Echocardiogram
- D. Natriuretic peptide
- E. Spirometry

# Question 2: Suspected cancer referrals

According to current NICE guidance on suspected cancer, **HOW MANY** adult patients referred in accordance with the specified criteria are predicted to have cancer? Select **ONE** option only.

- A. 1 in 100
- B. 2 in 100
- C. 3 in 100
- D. 5 in 100
- E. 10 in 100

# Question 3: Confidential Enquiry into Maternal Deaths

A 32-year-old pregnant woman has had a flu-like illness for 24 hours. She has a fever, cough and generalised aches. Her temperature is 38.1 °C. There is an influenza pandemic in the locality.

According to the Confidential Enquiry into Maternal Deaths, which of the following is the **MOST** appropriate treatment? Select **ONE** option only.

- A. Aciclovir
- B. Amantadine
- C. Amoxicillin
- D. Ibuprofen
- E. Oseltamivir

# Question 4: Bronchiolitis

A nine-month-old child has had a runny nose and now developed a cough. His temperature is 38 °C, respiratory rate 50 breaths/minute and he has bilateral wheeze. His oxygen saturation is 95%. You agree with his parents to manage him at home.

**According to current NICE guidance, which is the SINGLE MOST important clinical feature to prompt IMMEDIATE medical review? Select ONE option only.**

- A. Declining solid food
- B. Marked chest recession
- C. No wet nappy for six hours
- D. Sleepy child, waking with stimulation
- E. Temperature 39 °C

# Question 5: Drug-resistant hypertension

According to a recent study published in The Lancet, which is the **SINGLE MOST** effective fourth-line, add-on medication for the treatment of drug-resistant hypertension? Select **ONE** option only.

- A. Bisoprolol
- B. Doxazosin m/r
- C. Hydralazine
- D. Methyldopa
- E. Spironolactone

# Suspected Cancer – Recognition and Referral


Dr Thomas Round

NICE (12) 2016

EKU17 written by Dr Matthew Castleden

# Overview

- Summarises recommendations in the 2015 NICE guideline (NG12) on the recognition of cancer in primary care
- Increase in lifetime cancer risk from approximately 1 in 3 to 1 in 2
- Identification of people with possible cancer usually happens in primary care
- Variation in referral and testing for possible cancer (independent of population characteristics) has prompted move to improve cancer diagnosis in primary care
- New primary care based evidence helped prompt review and need for updated guidance



## Source Documents:

Suspected Cancer: Recognition and Referral. National Institute for Health & Care Excellence (NICE) Guideline 12, 2015.

[www.nice.org.uk/guidance/ng12](http://www.nice.org.uk/guidance/ng12)

# Basic Principles

- Risk threshold in the 2005 guideline varied by cancer type but did not usually correspond to a positive predictive value (PPV) of less than 5%
- 2015 guideline uses a standardised PPV of 3% for all cancers (except children and young people, where PPVs are below 3%)
- This means that 3 out of 100 adult patients referred under the 2015 guideline could be expected to have cancer
- Three sections: the first organises recommendations according to cancer site; second covers patient support, safety netting and the diagnostic process; third presents the recommendations according to symptoms and investigation findings

# Recommendation organised by site of cancer

- There are **89 recommendations** in this section of the guideline, many updated since 2005 - impossible to adequately cover in one ECU module
- Some of the more **significant changes** are summarised in the following slides for **lung, upper and lower GI cancers**
- Language of the guideline generally less proscriptive, with more scope for clinicians to use own judgement
- Increased use of direct access investigations previously only available in secondary care
- Consequent NHS organisational and resource implications

# Lung

- Refer patients aged over 40 years with haemoptysis using a suspected cancer (2 week) referral pathway [regardless of any chest X-ray findings]
- Urgent (within 2 weeks) chest X-ray should offered to people over 40 with two or more of the following symptoms (or one or more if smoker or ex-smoker): cough, fatigue, SOB, chest pain and weight loss, and appetite loss
- If thrombocytosis is present in people aged over 40 an urgent CXR should be considered

# Upper GI

- Offer urgent direct access gastrointestinal endoscopy (within 2 weeks) to assess for oesophageal or stomach cancer in people with dysphagia, or aged 55 and over with weight loss and any of the following: upper abdominal pain, reflux, or dyspepsia
- Consider urgent direct access CT scan (within 2 weeks) to assess for pancreatic cancer in people aged over 60 with weight loss and alarm symptoms (including diarrhoea, back pain, abdominal pain) or with new onset diabetes
- Consider urgent direct access ultrasound for liver or gallbladder mass

# Lower GI

2 week referral for colorectal cancer for patients:

- Aged 40+ with unexplained weight loss and abdominal pain
- Aged 50+ with unexplained rectal bleeding [no longer a requirement for 6 weeks of bleeding]
- Aged 60+ with iron deficiency anaemia or changes in bowel habit [haemoglobin threshold no longer specified]

2 week referral recommended for a positive faecal occult blood (FOB) test.

FOB testing recommended in the following situations:

- People aged 50+ with unexplained abdominal pain or weight loss
- Under 60 with changes in bowel habit or iron deficiency anaemia
- Aged 60+ with anaemia even in the absence of iron deficiency


# Non-site-specific symptoms

- NICE recognise that some symptoms may be suggestive of one of several different cancers; although 'the risk of each individual cancer may be low... the total risk of cancer of any type may be higher'
- For children and young people, parents' insight and knowledge should be taken into account: can consider referral if persistent parental/carer concern even if symptoms most likely benign
- For adults, unexplained appetite loss, weight loss, and deep vein thrombosis should prompt further assessment for additional symptoms, signs and findings together with urgent investigation or referral for suspected cancer

# Recommendations by symptom & findings of primary care investigations

- NICE also organises guidance according to symptom presentation and initial investigation findings, rather than by cancer site
- A departure for NICE: innovative and potentially clinically useful (as it arranges guidance in the same way patients actually present)
- But the duplication of recommendations makes for a larger and more complex guideline
- Symptom groups listed alphabetically in guideline, but helpful visual representations of symptom-based NICE guidance have been published eg BMJ flow charts, CRUK infographics

# Recommendations by symptom & findings of primary care investigations



# Recommendations by symptom & findings of primary care investigations

Example: Haematuria (NICE guideline format)

Symptom and specific features	Possible cancer	Recommendation [relevant cancer site section]
Haematuria (visible and unexplained) either without UTI or persisting/recurring after successful treatment for UTI, 45 and over	Bladder or renal	Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) [1.6.4] [1.6.6]
Haematuria (non-visible and unexplained) with dysuria or raised WCC on a blood test, 60 and over	Bladder	Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) [1.6.4]
Haematuria (visible) with low Hb levels or thrombocytosis or high blood glucose levels or unexplained vaginal discharge in women 55 and over	Endometrial	Consider a direct access ultrasound scan [1.5.12]
Haematuria (visible) in men	Prostate	Consider a prostate-specific antigen (PSA) test and digital rectal examination [1.6.2]

# Practical Tips

Download and/or print the summary tables or infographics of guidelines organised by symptom presentation (see resources) for use during or immediately after consultations.

Remember unexplained thrombocytosis in an FBC result could signify an increased risk of cancer (e.g. suspected endometrial or lung cancer).

Appetite loss, weight loss, or unexplained DVT should prompt further investigation for suspected cancer.

Check that FOB testing is available in your area for non-screening purposes.

Check referral processes and availability of direct access investigations as recommended in the new guideline

# Essential Knowledge Update 18

## October 2016

Briefings/Minors/Journal Watch/Hot Topics

Dr Thomas Round

# Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. The Lancet, April 2016

- Analysis of GP and nurse consultations of patients at 398 English general practices between April 2007 – March 2014, including 101,818,352 consultations
- Annual consultation rate per person increased by 10.5%, from 4.67 in 2007–08, to 5.16 in 2013–14
- 12.36% increase in standardised GP consultation rates compared with 0.9% for practice nurses
- GP telephone consultation rates doubled, compared with a 5.20% rise in surgery consultations, which accounted for 90% of all consultations
- The mean duration of GP surgery consultations increased by 6.7%, from 8.65 min to 9.22 min
- Overall workload increased by 16%

# General practice funding underpins the persistence of the inverse care law: cross-sectional study in Scotland. BJGP, December 2015

- A cross-sectional study using routine data from 956 general practices in Scotland
- Levels of multi-morbidity rose with practice deprivation. Practices in the most deprived decile had
  - 38% more patients with multi-morbidity compared with the least deprived (222.8 per 1000 patients versus 161.1;  $P < 0.001$ )
  - >120% more patients with combined mental and physical multi-morbidity (113.0 per 1000 patients versus 51.5;  $P < 0.001$ )
  - 20% more consultations per annum compared with the least deprived (4616 versus 3846,  $P < 0.001$ )
- There was no association between total practice funding and deprivation
- There was no association between consultation rates and levels of funding

# Vaccines for preventing herpes zoster in older adults.

## Cochrane review, March 2016

- Review included 13 studies involving 69,916 participants
- Incidence of herpes zoster, at up to three years of follow-up, was lower in participants who received the vaccine than in those who received a placebo: risk ratio (RR) 0.49; 95% confidence interval (CI) 0.43 to 0.56, risk difference (RD) 2%, number needed to treat to benefit (NNTB) 50
- The authors conclude that herpes zoster vaccine is effective in preventing herpes zoster disease and this protection can last three years
- In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity

# Topical Nonsteroidal Anti-inflammatory Drugs for Acute Musculoskeletal Pain. JAMA, February 2016

- The review included 61 studies. Compared topical NSAIDs with a similar topical placebo; 5311 participants were treated with a topical NSAID, 3470 with placebo, and 220 with an oral NSAID
- Formulations of topical NSAIDs were associated with higher rates of clinical success (more participants with at least 50% pain relief) than matching topical placebo
- Topical diclofenac NNT 3.7; topical ketoprofen NNT 3.9; topical ibuprofen NNT 3.9. All other drugs in any formulation had NNT values above 4
- Local skin reactions associated with topical NSAIDs (4.3%) did not differ from placebo (4.6%) and were generally mild and transient
- Systemic adverse events occurred in 3% of participants for both NSAIDs and placebo

# Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis: A Randomized Clinical Trial. JAMA

- Randomised, single-blind trial conducted 2010 to 2015 in a paediatric emergency department in Toronto, Canada
- Study participants children aged 6 - 60 months with gastroenteritis and minimal dehydration
- 647 children (mean age, 28.3 months; boys 51%; 441 (68.2%) without evidence of dehydration) randomly assigned to receive half-strength apple juice/preferred fluids (n=323) or apple-flavoured electrolyte maintenance solution (n=324)
- Children given dilute apple juice experienced treatment failure less often than those given electrolyte maintenance solution (16.7% vs 25.0%)
- Fewer children administered apple juice/preferred fluids received intravenous rehydration (2.5% vs 9.0%)
- Hospitalisation rates and diarrhoea and vomiting frequency were not significantly different between groups



**RCGP Learning**

Essential CPD for primary care

# Type 2 Diabetes – Management in adults

**Dr Chris Elfes FRCGP**

NICE (NG28) July 2016

EKU18 written by Dr Maitram Tran



Royal College of  
General Practitioners

# What's 'new'?

- Prevalence 6-6.7%
- Do *not* recommend dietary products specifically marketed for DM
- Do *not* recommend antiplatelet as primary prevention
- Seek advice if unexplained differences HbA<sub>1c</sub> vs glucose

# What else is different?

- Individualised care
- Informed decision making
- Working in partnership with a person with DM
- Acknowledgement that studies are ‘younger’ adults age 45-68

# Blood pressure targets

- < 140/80
- < 130/80 if renal/eye/CVS co-morbidity
  
- Monitor BP 1- 2 monthly until target is achieved
- Monitor BP 4-6 monthly once target is achieved

# Antihypertensive medication

## Individualise care

- 1<sup>st</sup> -line ▷ ACE *except*:
  - If Afro Caribbean ▷ DUAL therapy ACE + CCB or Thiazide
  - If pregnant/planning pregnancy ▷ ? CCB\*
  - If intolerant of ACE ▷ ARB
- 2<sup>nd</sup> -line ▷ ACE + CCB or Thiazide
- 3<sup>rd</sup> -line ▷ ACE + CCB + Thiazide
- 4th-line ▷ ACE + CCB + Thiazide +  $\alpha$ -blocker
- or ACE + CCB + Thiazide + b-blocker
- or ACE + CCB + Thiazide + spironolactone

# Self-monitoring of blood glucose (SMBG)

## Regular SMBG only if:

- Insulin
- Evidence of hypo's
- Antidiabetic agents increasing hypo risk driving/occupation
- Pregnant
- Planning to be pregnant

## Short-term SMBG\* if:

- Starting oral steroids
- Starting IV steroids
- To confirm/exclude diagnosis if unclear? Hypo's

# HbA<sub>1c</sub> Targets (non-pregnant)

Monitor 3-6 monthly from diagnosis Monitor 6-monthly once stable	HbA <sub>1c</sub> target	Comment
Diet controlled or Monotherapy with Metformin, Pioglitazone or Gliptin	48 mmol/mol (6.5%)	Unless drug-associated hypo's Reinforce lifestyle
If monotherapy control deteriorates to 58+ mmol/mol or If monotherapy with sulfonylurea If drug associated hypoglycaemia with 48 mmol/mol	53 mmol/mol (7%)	Reinforce lifestyle Check adherence Add second drug
If elderly, frail, reduced life expectancy, falls associated with hypo, poor hypo awareness or If occupation involves driving/machinery etc	Relax target on a case- by-case basis	<i>Upto 64 mmol/mol (8%)</i> <i>Upto 68 mmol/mol (8.4%)</i> <i>Avoid symptomatic hyperglycaemia</i>
If unexpected low HbA <sub>1c</sub>		Consider if unintentional weight loss Check for anaemia Check for reduced renal function

**Individualise care**

# Antidiabetic agents 1

## Individualise care

*If symptomatic from hyperglycaemia then consider admission, insulin or sulfonylurea and early review*

### 1<sup>st</sup> line ▸ Metformin

- Metformin m/r
- Gliptin or Pioglitazone\* or Sulfonylurea

### 1<sup>st</sup> Intensification

- DUAL therapy ▸ Met + Gliptin or Pio or Sulfonylurea
- DUAL therapy ▸ Gliptin + Pio, or Gliptin + Sulfonylurea, or Pio + Sulfonylurea
  
- *Consider DUAL therapy ▸ Met + Glinide*
- *Consider DUAL therapy with SGLT-2*

# Antidiabetic agents 2

Individualise care

## 2<sup>nd</sup> Intensification

- TRIPLE therapy ▷ Met + Gliptin + Sulfonylurea  
or
- TRIPLE therapy ▷ Met + Pio + Sulfonylurea  
or
- TRIPLE therapy ▷ Met + (Pio or Sulfonylurea) + SGLT2  
or
- Insulin +/- Metformin

## Consider

- TRIPLE therapy\* ▷ Met + Sulfonylurea + GLP1 injections
- Specialist only ? Insulin + GLP1 injections

## ADULT WITH TYPE 2 DIABETES WHO CAN TAKE METFORMIN

### If HbA1c rises to 48 mmol/mol (6.5%) on lifestyle interventions:

- Offer standard-release metformin
- Support the person to aim for an HbA1c level of 48 mmol/mol (6.5%)

If standard-release metformin is not tolerated, consider a trial of modified-release metformin

### FIRST INTENSIFICATION

#### If HbA1c rises to 58 mmol/mol (7.5%):

- Consider dual therapy with:
  - metformin and a DPP-4i
  - metformin and pioglitazone<sup>a</sup>
  - metformin and an SU
  - *metformin and an SGLT-2<sup>b</sup>*
- Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%)

If triple therapy is not effective, not tolerated or contraindicated, consider combination therapy with metformin, an SU and a GLP-1 mimetic<sup>c</sup> for adults with type 2 diabetes who:

- have a BMI of 35 kg/m<sup>2</sup> or higher (adjust accordingly for people from black, Asian and other minority ethnic groups)
- and** specific psychological or other medical problems associated with obesity **or**
- have a BMI lower than 35 kg/m<sup>2</sup>, **and** for whom insulin therapy would have significant occupational implications, **or** weight loss would benefit other significant obesity-related comorbidities

### SECOND INTENSIFICATION

#### If HbA1c rises to 58 mmol/mol (7.5%):

- Consider:
  - triple therapy with:
    - o metformin, a DPP-4i and an SU
    - o metformin, pioglitazone<sup>a</sup> and an SU
    - o *metformin, pioglitazone<sup>a</sup> or an SU, and an SGLT-2<sup>b</sup>*
  - insulin-based treatment
- Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%)

## METFORMIN CONTRAINDICATED OR NOT TOLERATED

### If HbA1c rises to 48 mmol/mol (6.5%) on lifestyle interventions:

- Consider one of the following<sup>d</sup>:
  - a DPP-4i, pioglitazone<sup>a</sup> or an SU
- Support the person to aim for an HbA1c level of 48 mmol/mol (6.5%) for people on a DPP-4i or pioglitazone **or** 53 mmol/mol (7.0%) for people on an SU

### FIRST INTENSIFICATION

#### If HbA1c rises to 58 mmol/mol (7.5%):

- Consider dual therapy<sup>e</sup> with:
  - a DPP-4i and pioglitazone<sup>a</sup>
  - a DPP-4i and an SU
  - pioglitazone<sup>a</sup> and an SU
- Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%)

### SECOND INTENSIFICATION

#### If HbA1c rises to 58 mmol/mol (7.5%):

- Consider insulin-based treatment
- Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%)

# Structured insulin advice

- Injection technique e.g. rotating sites,
- Continuing telephone support
- Self-monitoring
- Dose titration to target levels
- Dietary understanding
- DVLA at a glance guide\* (+ *TREND-UK*)
- Management of hypoglycemia
- Management of acute changes in plasma glucose control
- Support from an appropriately trained and experienced HCP

# Gastroparesis

- Symptoms
  - Unexplained vomiting
  - Unexplained bloating
  - Very variable glucose readings
- No strong evidence for drug treatment
  - 1. Metoclopramide alternating with Erythromycin
  - 2. *Exceptional circumstances* - Domperidone
- **Specialist opinion**

# Take home points

Personalised care tailored to the individual:

- Individual BP targets
- Individual HbA<sub>1c</sub> targets
- Relax HbA<sub>1c</sub> targets in the very frail/elderly
- Less Aspirin



**RCGP Learning**

Essential CPD for primary care

# Essential Knowledge Update 17

## April 2016

Briefings/Minors/Journal Watch/Hot Topics

Dr Chris Elfes FRCGP



Royal College of  
General Practitioners

# Oral anticoagulants for stroke prevention in AF

- Warfarin reduces the risk of stroke in non-valvular AF > 60%.
- But only used by 50% of those who should be on treatment.
- NOACs have been shown to be at least as good as warfarin for stroke prevention in AF
- NOACs have a fast onset and offset of action, 'better' safety profiles but they currently lack easily available specific antidotes.
- NOACs have **significantly lower** all-cause mortality compared with warfarin in large clinical trials.

Verheugt FWA, Granger CB.

[Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs. The Lancet, 386, 9990, 303-310.](#)

# Anticoagulation self-monitoring

- Patients vary considerably in their ability to self-monitor and self-manage
- Only 38% (range 12–59%) identified as eligible for self-monitoring actually do so

This was a prospective cohort study (N = 296) published in the BJGP:

- Median age 61
- 55% male
- 82.7% were professionals or held a university qualification

At 12 months :

- 90% were still self-monitoring.
- Mean TTR 75%
- Six serious and two minor adverse events were reported by GPs
- Only 46% received any face-to-face training at the outset
- Increased age (P = 0.027), general wellbeing (P = 0.020), and lower target INR ( P = 0.032) were all associated with high (>80% TTR) levels of control

# Hidradenitis suppurativa

## Cochrane review, 2015

- Estimated to affect up to 1% of the adult population
- There was no RCT evidence to support several common treatments
- Included trials were small and average duration was four months
- **Weak evidence of benefit** for clindamycin lotion and oral tetracyclines
- Pharmaceutical industry-sponsored trials of anti-TNF therapies:
  - Etanercept – no benefit
  - Infliximab – small trial, improved quality of life at 8 weeks
  - Adalimumab – N = 154, high-dose ‘probably’ improved quality of life at 16 weeks
- No trials investigating when or what surgical procedure to consider
- Quality too low to recommend laser-type treatments

# Leukotriene receptor antagonists (LTRAs) as maintenance and intermittent therapy for Episodic Viral Wheeze (EVW) in children

- ~30% of children experience a wheezing episode before age of five
- Many pre-school children only wheeze with URTIs (EVW)
- EVW appears to be a separate entity from atopic asthma
- This 2015 Cochrane review compared maintenance or intermittent LTRA with placebo in pre-school children with EVW
- Five eligible studies (N = 3741). All used oral montelukast with good methodology, but different outcome measures

**No evidence of benefit** of maintenance or intermittent LTRA treatment over placebo for preventing acute episodes of wheezing requiring use of rescue oral steroids

# Maternal health in pregnancy: messages from the 2014 UK Confidential Enquiry into Maternal Death

Maternal mortality has fallen to 10/100,000.

- The major cause of 'direct' deaths was thromboembolism.
- ~66% of deaths due to 'indirect causes' - cardiac, infections, medical problems and suicide.
- Maternal mortality is higher among older women, women living in the most deprived areas, Black African and Asian women (especially if born outside the UK)
- Only 29% of those who died had had the recommended level of antenatal care.

## Key messages for GPs include:

- All pregnant women should be strongly encouraged to have flu immunisation
- If a pregnant woman has flu/close contact with a FLI, treat with neuraminidase inhibitors (NAIs) a.s.a.p
- Potentially septic women should have obs recorded - HR, Temp, BP, and RR - and emergency admission
- If the condition of a pregnant woman with epilepsy changes she needs urgent review with a neurologist
- Proteinuria in early pregnancy should be quantified and, if found to be significant, investigated
- All women with pre-existing medical conditions need pre-pregnancy counselling

# Intermittent oral iron supplementation during pregnancy

- This Cochrane review assessed the benefits and harms of intermittent (i.e. two or three times a week on non-consecutive days) oral supplementation with iron or iron and folic acid or iron and vitamins and minerals for pregnant women
- 21 trials involving 5,490 women
- There was no clear evidence of worse outcomes for infant birthweight, premature birth, perinatal death, anaemia\* and iron deficiency in women at the end of pregnancy
- However, women receiving intermittent rather than daily iron supplements were:
  - Less likely to report side effects such as constipation and nausea
  - Less likely to develop high haemoglobin concentrations
  - There were no other clear benefits for other outcomes examined



**RCGP Learning**

Essential CPD for primary care

# Management of Chronic Heart failure

**Dr Dirk Pilat FRCGP**

SIGN (147) March 2016

EKU18 written by Dr Michael Thurgood



Royal College of  
General Practitioners

# Management of chronic heart failure

- Really common!
- Affecting 500,000 people in UK
- 1.22% of men and 0.76% of women in UK
- Becoming more prevalent as ageing population
- Still terrible prognosis

# Management of chronic heart failure

Two types:

- Heart failure with reduced ejection fraction (HF-REF)
- Heart failure with preserved ejection fraction (HF-PEF)

Discrimination via Echocardiogram

# Heart failure with preserved ejection fraction (HF-PEF)

- 35-50% of patients with HF
- Decrease in LV compliance
- Increase of pressure in LV

## Causes

- Myocardial Ischaemia
- Myocardial Hypertrophy
- Myocardial Constriction
- Pericardial Constriction
- Tachyarrhythmias

# HF – REF: Most Common Causes

- Coronary artery disease
- Diabetes mellitus
- Hypertension
- Valvular heart disease (stenosis or regurgitant lesions)
- Arrhythmia (supraventricular or ventricular)
- Infections and inflammation (myocarditis)
- Peripartum cardiomyopathy
- Congenital heart disease
- Drugs (either recreational, such as alcohol and cocaine, or therapeutic drugs with cardiac side effects)
- Idiopathic cardiomyopathy

# HF – REF: Symptoms and Signs

- Dyspnoea, Orthopnoea, Nocturnal Dyspnoea
- Reduced Exercise Tolerance
- Elevated Jugular Pressure
- Third Heart Sound
- Cardiac Murmur
- Laterally Displaced Apex Beat

# HF – REF: Workup

- BNP
  - If > 400, 2ww referral to cardiology
  - If 100-400, echo within 6 weeks
- ECG
- Echo: <40% ejection fraction diagnostic
- CXR
- FBC, U+E's, Urine dipstick, HbA1c, TFTs

# HF – REF: Lifestyle Changes

- Low Salt Diet
- Smoking Cessation
- Weight Monitoring
- Supervised Exercise
- Influenza and Pneumococcal immunisation

# HF – REF: Treatment

- ACE-I / ARB
- Beta-blocker (even in COPD!)
- Loop Diuretic if still symptomatic
- MRA if still symptomatic
- If Spironolactone not tolerated, try Eplerenone
- If MRA not tolerated, trial of ARB+ACE-I
- ARB/Nepriylsin Inhibitor
- Ivabradine
- Digoxin

# HF – REF: Palliative care

- Active heart failure management and symptom control
- Rationalisation of drug therapy
- Anticipatory care planning
- Coordination of care involving a multidisciplinary team with good communication between specialities
- End of life care

# HF – REF: Service Needs

- Audit renal function monitoring
  - Heart failure patients
  - Patients on ACE-I/ARB/Spiroonolactone/Eplenerone
- Push CCG re access to BNP/Echo



**RCGP Learning**

Essential CPD for primary care

# Bronchiolitis in Children: Diagnosis and Management

**Dr Thomas Round**

NICE (9) 2015

EKU17 written by Dr Amer Salim



Royal College of  
General Practitioners

# Overview

- Evidence based approach to the diagnosis and management of bronchiolitis in children
- Summary of NICE guideline 2015
- Also information on how to recognise children who may require hospital management

## Source Documents:

Bronchiolitis in Children: National Institute of Health and Care Excellence (NICE) Guideline 9, 2015

[www.nice.org.uk/guidance/ng9](http://www.nice.org.uk/guidance/ng9)



# Introduction

- A common acute viral illness that affects the lower respiratory tract
- Generally occurs in children under one year
- Approximately, one in three children are affected in the first year of life
- Seasonal infection that peaks in winter months
- Most common causative agent is respiratory syncytial virus (RSV)
- Associated with an increased risk of asthma
- Risk factors for bronchiolitis are:
  - Congenital heart disease
  - Neuromuscular disorders
  - Immunodeficiency
  - Chronic lung disease

# Basic Principles

- Usually a mild, self-limiting acute viral illness that requires no specific treatment
- A clinical diagnosis, careful clinical assessment to differentiate from viral-induced wheeze and pneumonia
- Deteriorating disease requires consideration for hospital referral
- Alarm symptoms or signs warrant emergency hospital referral
- Parents need safety information on how to recognise 'red flag' symptoms

# Diagnosis

Bronchiolitis affects children under two years of age and most commonly in the first year of life, peaking between three and six months.

Diagnose bronchiolitis if a child has coryzal prodromal symptoms lasting one to three days, followed by:

- Persistent cough

**AND**

- Either tachypnoea or chest recession (or both)

**AND**

- Either wheeze or crackles on chest auscultation

# Differential diagnosis

Clinical features of bronchiolitis overlap with pneumonia and viral-induced wheeze.

## Pneumonia

- Consider pneumonia if the child has:
- High fever (over 39°C) and/or
- Persistent focal crackles

## Viral-induced wheeze

- Consider in older infants and young children if they have any of the following:
- Persistent wheeze without crackles or
- Recurrent episodic wheeze or
- A personal or family history of atopy

# Alarm symptoms

Following warrant immediate referral to hospital care:

- Apnoea: observed or reported
- Severe respiratory distress: grunting, marked chest recession or RR over 70 breaths/minute
- Central cyanosis
- Persistent oxygen saturation of less than 92% on air
- Seriously unwell looking child

Consider referral to hospital in the following situations:

- RR over 60 breaths/minute
- Difficulty with breastfeeding or inadequate oral fluid intake (50-75% of usual volume)
- Clinical dehydration

# Management in primary care

Bronchiolitis is usually a mild, self-limiting illness that can be managed at home without the need for any specific treatment.

The following treatments are **NOT** recommended:

- Antibiotics
- Bronchodilators
- Oral or inhaled corticosteroids
- Montelukast
- Steam inhalation

# Safety netting

The parents and carers of children with bronchiolitis who are managed at home need to be able to recognise 'red flag' symptoms and understand how to access healthcare urgently.

Written or online safety information should be provided.

- **Work of breathing:** grunting, nasal flaring, marked chest recession
- **Fluid intake:** 50-75% of normal or no wet nappy for 12 hours
- **Exhaustion:** not responding normally to social cues, wakes only with prolonged stimulation
- **Apnoea**

# Management: Hospital Care

Aim of hospitalisation is to provide supportive care

- Nasal suction to facilitate oral feeds
- Hydration – nasogastric or intravenous
- Oxygen if saturation is persistently less than 92%
- Continuous positive airway pressure (CPAP) with impending respiratory failure
- Upper airway suction with respiratory distress or feeding difficulties because of upper airway secretions or with apnoea even if there are no obvious upper airway secretions

NICE recommends avoiding the following drugs:

- Antibiotics
- Hypertonic saline
- Adrenaline – nebulised
- Salbutamol
- Montelukast
- Ipratropium bromide
- Systemic or inhaled corticosteroids
- Combination of systemic corticosteroids and nebulised adrenaline

# Practical Tips

Consider bronchiolitis in a child who has coryzal symptoms associated cough and tachypnoea.

Explore features of the history and examination that help distinguish bronchiolitis from other causes of lower respiratory tract infections and wheeze.

Emphasise the need to avoid unnecessary treatment for mild cases of the disease.

Provide information for parents and carers on how to recognise deteriorating disease and 'red flag' symptoms.

# Question 1

## Investigation of cough

A 68-year-old ex-smoker has had a dry cough for eight weeks. Examination is normal. He has COPD and hypertension. His regular medications are: aspirin 75 mg daily, atorvastatin 80 mg daily, amlodipine 5 mg daily and tiotropium inhaler once daily.

Which of the following is the **SINGLE MOST** appropriate **INITIAL** investigation? Select **ONE** option only.

- A Chest x-ray
- B ECG
- C Echocardiogram
- D Natriuretic peptide
- E Spirometry

# Question 2

## Suspected cancer referrals

According to current NICE guidance on suspected cancer, **HOW MANY** adult patients referred in accordance with the specified criteria are predicted to have cancer? Select **ONE** option only.

- A 1 in 100
- B 2 in 100
- C 3 in 100
- D 5 in 100
- E 10 in 100

## Question 3

# Confidential Enquiry into Maternal Deaths

A 32-year-old pregnant woman has had a flu-like illness for 24 hours. She has a fever, cough and generalised aches. Her temperature is 38.1 °C. There is an influenza pandemic in the locality.

According to the Confidential Enquiry into Maternal Deaths, which of the following is the MOST appropriate treatment? Select ONE option only.

- A Aciclovir
- B Amantadine
- C Amoxicillin
- D Ibuprofen
- E **Oseltamivir**

# Question 4

## Bronchiolitis

A nine-month-old child has had a runny nose and now developed a cough. His temperature is 38 °C, respiratory rate 50 breaths/minute and he has bilateral wheeze. His oxygen saturation is 95%. You agree with his parents to manage him at home.

According to current NICE guidance, which is the SINGLE MOST important clinical feature to prompt immediate medical review? Select ONE option only.

- A Declining solid food
- B Marked chest recession**
- C No wet nappy for six hours
- D Sleepy child, waking with stimulation
- E Temperature 39 °C

# Question 5

## Drug-resistant hypertension

According to a recent study published in The Lancet, which of the following is the **SINGLE MOST** effective fourth-line, 'add-on' medication for the treatment of drug-resistant hypertension? Select **ONE** option only.

- A Bisoprolol
- B Doxazosin m/r
- C Hydralazine
- D Methyldopa
- E **Spirolactone**

# The RCGP eLearning Team

Thank you

- **Dragana Milosevic**, Education & Projects Manager
- **Katie Hopkins**, Education Project Officer
- **Beverley Berry**, CPD Research Officer
- **Priya Chudasama**, Knowledge Test Manager
- **Damian Bardiger**, Senior Web Developer (OLE)

# Take home points and permission to give feedback!

